Skip to content
Research Article Open access CC BY 4.0

The Controversies Surrounding Bevacizumab and Ranibizumab

Ee Vien Low, Faridah Aryani Md. Yusof

Advances in Research · pp. 334–340 · Published 24 Oct 2014

10.9734/AIR/2015/13322

Abstract

Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness. Both bevacizumab and ranibizumab are anti-vascular endothelial growth factors used for treatment of AMD. However the use of bevacizumab remains controversial as it was not approved for intravitreal use although there were several head-to-head comparison trial that shows that it was non inferior to ranibizumab. Despite the status of off-label, intravitreal bevacizumab is being used worldwide as it is 30-50 times cheaper than intravitreal ranibizumab. The case of intravitreal bevacizumab illustrates the use of “not-me” drug and different countries responds differently to its use.

Age-related macular degeneration bevacizumab ranibizumab anti-vascular endothelial growth factor

References (15)

  1. 1 Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration [DOI]
  2. 2 Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration [DOI]
  3. 3 Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial [DOI]
  4. 4 Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial [DOI]
  5. 5 A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration [DOI]
  6. 6 BEVACIZUMAB VERSUS RANIBIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION [DOI]
  7. 7 Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials [DOI]
  8. 8 The off-label use of medication: the latest on the Avastin - Lucentis debacle.
  9. 9 Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD [DOI]
  10. 10 The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package [DOI]
  11. 11 Intravitreal Bevacizumab for Radiation-Induced Cystoid Macular Oedema in Patients with Nasopharyngeal Carcinoma: A Clinical Series [DOI]
  12. 12 Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials [DOI]
  13. 13 The Adjunctive Use of Anti-vascular Endothelial Growth Factor Agents in the Management of Iris Neovascularisation in Malaysia.
  14. 14 Roche and Novartis colluded over wet AMD drugs, says Italian regulator [DOI]
  15. 15 Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

28

Page views

0

PDF downloads

3

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.